Virtual Library

Start Your Search

Hideaki Shiraishi



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      4P - Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma (ID 245)

      12:30 - 13:00  |  Author(s): Hideaki Shiraishi

      • Abstract
      • Slides

      Background

      FRα is present on the cell surface, mediates its intracellular transport via receptor-mediated endocytosis, and is also involved in cell division. FRα is expressed at high levels on various cancer cells, and it is considered that FRα could be a potential therapeutic target in FRα-expressing cancers.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      We investigated the correlations between FRα expression in tissue microarray (TMA) constructed from surgical specimens of lung adenocarcinoma (LADC) and clinicopathological features including EGFR mutation retrospectively. Two TMA cores per a resected LADC specimen were created using TMA Master (3DHISTECH, Budapest, Hungary) at National Cancer Center Hospital between January 2007 and November 2016. Based on previous studies, if the percentage of stained tumor cells was greater than or equal 5%, FRα was considered as positive, and if H-score was more than or equal 60 (range, 0-300), FRα was considered as high expression.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Overall, 466 TMA cores created from 233 patients who underwent surgery for LADC were evaluated; FRα positive expression (FRα-pos)/negative (FRα-neg), 222/11; FRα high expression (FRα-HE)/low (FRα-LE), 190/43, respectively. 124 patients (53.2%) were with EGFR mutation. The median H-scores of FRα expression, rates of FRα-pos, and rates of FRα-HE for EGFR mutation and wild type were 159/104 (p = 0.0002), 97.6/92.7% (p = 0.077), and 88.7/73.4% (p = 0.0026). The median disease free survival (months) were 18.7/23.3 (p = 0.30) for FRα-pos/neg and 20.2/12.8 (p = 0.42) for FRα-HE/LE, respectively. The median overall survival were 92.9/not reached (p = 0.42) for FRα-pos/neg and 92.9/96.4 (p = 0.42) for FRα-HE/LE, respectively. FRα expression was not considered as a prognostic factor in LADC. 82 patients with EGFR mutation received EGFR-TKI after recurrence (FRα-pos/neg, 79/3; FRα-HE/LE, 71/11). Overall response rates and median progression free survival (months) of EGFR-TKI were 59.2/66.6% (p = 0.80) and 16.1/11.5 (p = 0.016) for FRα-pos/neg; 61.8/45.5% (p = 0.31) and 16.2/13.2 (p = 0.95) for FRα-HE/LE, respectively.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      FRα expression was significantly higher in LADC with EGFR mutation than that with wild-type. The efficacy of EGFR-TKI was better in FRα-pos than in FRα-neg.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      Y. Fujiwara: Research funding: AbbVie, AstraZeneca, BMS, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Incyte, Merck Serono, MSD, Novartis; Advisory role: AstraZeneca, BMS, MSD, Novartis, ONO; Speakers bureau: AstraZeneca, BMS, MSD, Novartis, ONO, Sysmex, Taiho. S. Kitano: Personal fee, grant: Eisai; Honoraria: ONO, Bristol-Myers Squibb, AstraZeneca, Chugai, Pfizer, Sanofi, Nippon Kayaku, Boehringer Ingelheim, Meiji, Taiho, Novartis, Daiichi Sankyo, MSD, Kirin, Celgene, Sumitomo Dainippon; Grant: Regeneron, Astellas, Gilead, AMED, JSPS. T. Shimizu: Advisory board: Takeda, The Consortium on Harmonization of Institutional Requirements for Clinical Research; Corporate sponsored research: Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Novartis, Eisai, Takeda, PharmaMar, FivePrime, 3D-Medicine, Symbio, Chordia. N. Yamamoto: Grants: Quintiles, Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kirin, Takeda, ONO, Janssen, Lilly, MSD, Merck; Advisory: Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic; Speakers: BMS, Pfizer, AstraZeneca, Lilly, ONO, Chugai. N. Motoi: Personal fee (lecture, Advisory board): Bristol-Myers Squibb, Miraca Life Sciences, AstraZeneca, Chugai Pharma, MSD, Agilent, Novartis, Roche Diagnostics; Institutional research funding: Roche Diagnostics. All other authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.